Compare CISO & QNME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CISO | QNME |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Integrated Freight & Logistics |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 14.1M |
| IPO Year | 2021 | 2024 |
| Metric | CISO | QNME |
|---|---|---|
| Price | $0.19 | $0.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 189.8K | ★ 4.1M |
| Earning Date | 11-12-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.31 | 47.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,850,681.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 111.79 |
| 52 Week Low | $0.16 | $0.26 |
| 52 Week High | $1.23 | $1.40 |
| Indicator | CISO | QNME |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 42.41 |
| Support Level | N/A | $0.29 |
| Resistance Level | $0.26 | $0.94 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 59.12 | 5.98 |
CISO Global Inc provides cybersecurity compliance and is a software firm composed of trained and seasoned security professionals. The services are used to protect clients' data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in the U.S., Chile, and all other countries. The maximum revenue is generated from the U.S. The products and services include: security managed services, professional services, and cybersecurity software.
Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.